GLS - GLS STOCK NEWS

Gelesis reported a 312% increase in Q2 2022 product revenue, reaching $9.0 million, compared to Q2 2021. Gross profit rose significantly to $4.2 million with a gross margin of 47%. The company added 43,800 new members, a 208% year-over-year increase, while maintaining a net loss of $(12.5) million. Despite positive growth indicators and new financing initiatives, Gelesis revised its fiscal year guidance downward, now expecting $27.0 million to $30.0 million in product revenue.

Gelesis Holdings, Inc. (NYSE:GLS) announced it will report Q2 financial results for the period ending June 30, 2022, on August 15, 2022, before market open. The management will host a conference call at 8:30 a.m. ET on the same day. Gelesis is known for its weight management product, Plenity®, which is FDA-cleared and made from naturally derived materials. The company is focused on expanding its portfolio, including potential therapies for Type 2 Diabetes and Non-alcoholic Fatty Liver Disease.

Gelesis (NYSE:GLS) announced a $15 million pre-paid order from telehealth partner Ro for its weight management product, Plenity. This adds to the $40 million in prior pre-orders, totaling $45 million in the past year. Since launching a national awareness campaign on January 31, 2022, Gelesis has seen a 140% increase in prescription requests and reported $7.5 million in net product revenue for Q1 2022, a 142% rise from Q1 2021. Plenity targets a large market, with 150 million Americans potentially qualifying for treatment.

Gelesis (NYSE: GLS) presented new findings at the American Diabetes Association's annual conference, revealing a significant lack of person-first language in scientific literature on obesity and diabetes. The analysis of over 100,000 scholarly articles from 2011-2020 showed that less than 1% utilized this language in obesity articles, although its usage in diabetes literature has increased over the years. The findings highlight ongoing stigmatization and the need for improvement in healthcare communication. Gelesis aims to combat this bias through its products and initiatives.

Gelesis (NYSE: GLS) presented new preclinical data at the American Diabetes Association’s annual conference showing that its proprietary superabsorbent hydrogel leads to weight loss and improved glucose tolerance in mice. This study demonstrated that microbiota transplants from Gel-B-treated mice to untreated mice resulted in weight loss, suggesting a potential mechanism for its metabolic benefits. This data follows earlier findings that hydrogel treatment positively affects gut microbiota composition, suggesting its application could extend to other metabolic conditions.

Gelesis (NYSE: GLS) announced that its CEO Yishai Zohar, CFO Elliot Maltz, and COO David Pass will participate in two upcoming investor conferences. The first event is the UBS Global Healthcare Conference on May 25, 2022, with a presentation at 8:30 a.m. ET. Attendees can join the live webcast here.

The second event is the Loop Capital Conference on June 1, 2022, participated virtually. Gelesis is known for Plenity, a FDA-cleared solution for weight management.

Gelesis (NYSE: GLS) reported a significant financial boost in Q1 2022, with net product revenue reaching $7.5 million, a 142% increase from Q1 2021, fueled by a national media campaign. Gross margin surged to 34.6%, up from 9.2% the previous year. The company acquired 40,400 new members, marking a 187% increase. Despite these gains, it reported a net loss of $(5.7) million. Looking ahead, Gelesis maintains a revenue guidance of $58 million for 2022, contingent on market dynamics and financing.

Gelesis (NYSE: GLS) will report its Q1 2022 financial results on May 12, 2022, after market close. A live conference call is scheduled for 4:30 p.m. ET on the same day, where management will discuss the results. Gelesis is well-known for its weight management product, Plenity®, and is actively involved in developing therapies for various conditions, including Type 2 Diabetes. Interested parties can access the call via the Gelesis Investor Relations website, with an archived version available shortly after the event.

Gelesis' LIGHT-UP clinical trial demonstrated that GS200, an oral superabsorbent hydrogel, effectively aids weight loss in adults with prediabetes or type 2 diabetes. About 60% of participants experienced at least a 5% decrease in body weight, averaging a loss of 11% (about 23 pounds) in just six months. Furthermore, roughly one-third were 'super responders,' losing over 10% of their body weight. The safety profile of GS200 was comparable to the placebo, indicating a promising new avenue in weight management for at-risk populations.